In Vivo Animal Stroke Models: A Rationale for Rodent and Non-Human Primate Models

Naoki Tajiri, Travis Dailey, Christopher Metcalf, Yusef I. Mosley, Tsz Lau, Meaghan Staples, Harry van Loveren, Seung U. Kim, Tetsumori Yamashima, Takao Yasuhara, Isao Date, Yuji Kaneko, Cesario V. Borlongan

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

On average, every 4 min an individual dies from a stroke, accounting for one out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack Roger et al. (Circulation, 125(1): 188-197, 2012). There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.

Original languageEnglish
Pages (from-to)308-321
Number of pages14
JournalTranslational Stroke Research
Volume4
Issue number3
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Primates
Rodentia
Animal Models
Stroke
Cell- and Tissue-Based Therapy
Stem Cells
Clinical Trials
Therapeutics

Keywords

  • Animals
  • Basic research
  • Cerebral ischemia
  • Clinical application
  • Translational

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Tajiri, N., Dailey, T., Metcalf, C., Mosley, Y. I., Lau, T., Staples, M., ... Borlongan, C. V. (2013). In Vivo Animal Stroke Models: A Rationale for Rodent and Non-Human Primate Models. Translational Stroke Research, 4(3), 308-321. https://doi.org/10.1007/s12975-012-0241-2

In Vivo Animal Stroke Models : A Rationale for Rodent and Non-Human Primate Models. / Tajiri, Naoki; Dailey, Travis; Metcalf, Christopher; Mosley, Yusef I.; Lau, Tsz; Staples, Meaghan; van Loveren, Harry; Kim, Seung U.; Yamashima, Tetsumori; Yasuhara, Takao; Date, Isao; Kaneko, Yuji; Borlongan, Cesario V.

In: Translational Stroke Research, Vol. 4, No. 3, 06.2013, p. 308-321.

Research output: Contribution to journalArticle

Tajiri, N, Dailey, T, Metcalf, C, Mosley, YI, Lau, T, Staples, M, van Loveren, H, Kim, SU, Yamashima, T, Yasuhara, T, Date, I, Kaneko, Y & Borlongan, CV 2013, 'In Vivo Animal Stroke Models: A Rationale for Rodent and Non-Human Primate Models', Translational Stroke Research, vol. 4, no. 3, pp. 308-321. https://doi.org/10.1007/s12975-012-0241-2
Tajiri, Naoki ; Dailey, Travis ; Metcalf, Christopher ; Mosley, Yusef I. ; Lau, Tsz ; Staples, Meaghan ; van Loveren, Harry ; Kim, Seung U. ; Yamashima, Tetsumori ; Yasuhara, Takao ; Date, Isao ; Kaneko, Yuji ; Borlongan, Cesario V. / In Vivo Animal Stroke Models : A Rationale for Rodent and Non-Human Primate Models. In: Translational Stroke Research. 2013 ; Vol. 4, No. 3. pp. 308-321.
@article{ce21b37748914706be804f5169896f7d,
title = "In Vivo Animal Stroke Models: A Rationale for Rodent and Non-Human Primate Models",
abstract = "On average, every 4 min an individual dies from a stroke, accounting for one out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack Roger et al. (Circulation, 125(1): 188-197, 2012). There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.",
keywords = "Animals, Basic research, Cerebral ischemia, Clinical application, Translational",
author = "Naoki Tajiri and Travis Dailey and Christopher Metcalf and Mosley, {Yusef I.} and Tsz Lau and Meaghan Staples and {van Loveren}, Harry and Kim, {Seung U.} and Tetsumori Yamashima and Takao Yasuhara and Isao Date and Yuji Kaneko and Borlongan, {Cesario V.}",
year = "2013",
month = "6",
doi = "10.1007/s12975-012-0241-2",
language = "English",
volume = "4",
pages = "308--321",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "3",

}

TY - JOUR

T1 - In Vivo Animal Stroke Models

T2 - A Rationale for Rodent and Non-Human Primate Models

AU - Tajiri, Naoki

AU - Dailey, Travis

AU - Metcalf, Christopher

AU - Mosley, Yusef I.

AU - Lau, Tsz

AU - Staples, Meaghan

AU - van Loveren, Harry

AU - Kim, Seung U.

AU - Yamashima, Tetsumori

AU - Yasuhara, Takao

AU - Date, Isao

AU - Kaneko, Yuji

AU - Borlongan, Cesario V.

PY - 2013/6

Y1 - 2013/6

N2 - On average, every 4 min an individual dies from a stroke, accounting for one out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack Roger et al. (Circulation, 125(1): 188-197, 2012). There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.

AB - On average, every 4 min an individual dies from a stroke, accounting for one out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack Roger et al. (Circulation, 125(1): 188-197, 2012). There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.

KW - Animals

KW - Basic research

KW - Cerebral ischemia

KW - Clinical application

KW - Translational

UR - http://www.scopus.com/inward/record.url?scp=84877129320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877129320&partnerID=8YFLogxK

U2 - 10.1007/s12975-012-0241-2

DO - 10.1007/s12975-012-0241-2

M3 - Article

C2 - 23682299

AN - SCOPUS:84877129320

VL - 4

SP - 308

EP - 321

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 3

ER -